CN110121343B - 用作gpr120调节剂的双环化合物 - Google Patents

用作gpr120调节剂的双环化合物 Download PDF

Info

Publication number
CN110121343B
CN110121343B CN201780068712.9A CN201780068712A CN110121343B CN 110121343 B CN110121343 B CN 110121343B CN 201780068712 A CN201780068712 A CN 201780068712A CN 110121343 B CN110121343 B CN 110121343B
Authority
CN
China
Prior art keywords
compound
mmol
preparation
mammals
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780068712.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110121343A (zh
Inventor
布里安·雷蒙多
埃莱娜·S·科尔通
约翰·格里芬
埃里克·施坦格兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valo Health Inc
Original Assignee
Overall Health
Numerate Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Overall Health, Numerate Inc filed Critical Overall Health
Publication of CN110121343A publication Critical patent/CN110121343A/zh
Application granted granted Critical
Publication of CN110121343B publication Critical patent/CN110121343B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780068712.9A 2016-09-12 2017-09-11 用作gpr120调节剂的双环化合物 Active CN110121343B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393619P 2016-09-12 2016-09-12
US62/393,619 2016-09-12
PCT/US2017/050964 WO2018049328A1 (en) 2016-09-12 2017-09-11 Bicyclic compounds useful as gpr120 modulators

Publications (2)

Publication Number Publication Date
CN110121343A CN110121343A (zh) 2019-08-13
CN110121343B true CN110121343B (zh) 2023-11-03

Family

ID=61562078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780068712.9A Active CN110121343B (zh) 2016-09-12 2017-09-11 用作gpr120调节剂的双环化合物

Country Status (6)

Country Link
US (2) US10865201B2 (enExample)
EP (1) EP3509588B1 (enExample)
JP (1) JP7065081B2 (enExample)
KR (1) KR102539877B1 (enExample)
CN (1) CN110121343B (enExample)
WO (1) WO2018049328A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110225752B (zh) 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
US10865201B2 (en) * 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
WO2019202612A2 (en) * 2018-04-20 2019-10-24 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
CN111499592B (zh) * 2020-03-14 2023-06-23 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法
CN111574414A (zh) * 2020-05-20 2020-08-25 上海毕得医药科技有限公司 一种4-溴-2-甲氧基苯磺酰氯的合成方法
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
CN114685395A (zh) * 2020-12-29 2022-07-01 浙江大学 一种2,3-二氢苯并[d]异噻唑类化合物及其应用
WO2024046323A1 (zh) * 2022-08-29 2024-03-07 山东大学 一种苯并五元氮环类化合物、其制备方法及医药用途
CN116730945B (zh) * 2023-08-10 2023-11-17 北京惠宇乐邦环保科技有限公司 糖精的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0548934A1 (en) * 1991-12-25 1993-06-30 Mitsubishi Chemical Corporation Benzamide derivatives
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
CN101500995A (zh) * 2006-03-17 2009-08-05 美国政府卫生与公共服务部 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物
WO2010104195A1 (en) * 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
TW201200505A (en) * 2010-06-17 2012-01-01 Metabolex Inc GPR120 receptor agonists and uses thereof
WO2014096941A1 (en) * 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
CN105209444A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 可用作gpr120的激动剂的苯并稠合杂环衍生物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735225A (en) 1956-02-21 Table ix p petri dish tests with x-phthalimido-
DE2253251A1 (de) 1972-10-30 1974-05-09 Thomae Gmbh Dr K Neue phthalimido-sulfonylharnstoffe
DE3474547D1 (en) * 1983-12-02 1988-11-17 Shell Int Research Diphenyl ether herbicides
FR2659327A1 (fr) 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
DE69224115T2 (de) 1991-07-30 1998-08-20 Ciba Geigy Ag Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
US6716836B2 (en) * 2001-03-22 2004-04-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
MY150746A (en) * 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
JP5175866B2 (ja) 2007-02-22 2013-04-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体を調節するための化合物および方法
KR101511396B1 (ko) 2007-07-20 2015-04-13 추가이 세이야쿠 가부시키가이샤 ｐ27 단백질 유도제
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8314120B2 (en) * 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
EP2582674B1 (en) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
AR088989A1 (es) 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
CA2887348A1 (en) 2012-10-11 2014-04-17 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
RU2015123982A (ru) 2012-12-03 2017-01-13 Ф. Хоффманн-Ля Рош Аг Соединения замещенных триазола и имидазола
CA2905729C (en) 2013-03-14 2021-11-09 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
ES2784489T3 (es) 2013-06-27 2020-09-28 Lg Chemical Ltd Derivados de biarilo como agonistas de GPR120
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AR100328A1 (es) 2014-05-07 2016-09-28 Bristol Myers Squibb Co Moduladores pirrolidina de gpr40
JP2017527559A (ja) 2014-08-29 2017-09-21 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
JP6486699B2 (ja) 2015-01-29 2019-03-20 国立大学法人金沢大学 脱水縮合剤
ES2989326T3 (es) * 2015-10-21 2024-11-26 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteína cinasa
CN110225752B (zh) * 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
US10865201B2 (en) * 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
EP0548934A1 (en) * 1991-12-25 1993-06-30 Mitsubishi Chemical Corporation Benzamide derivatives
CN101500995A (zh) * 2006-03-17 2009-08-05 美国政府卫生与公共服务部 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物
WO2010104195A1 (en) * 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
TW201200505A (en) * 2010-06-17 2012-01-01 Metabolex Inc GPR120 receptor agonists and uses thereof
WO2014096941A1 (en) * 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
CN105209444A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 可用作gpr120的激动剂的苯并稠合杂环衍生物

Also Published As

Publication number Publication date
EP3509588A1 (en) 2019-07-17
JP2019533642A (ja) 2019-11-21
JP7065081B2 (ja) 2022-05-11
EP3509588A4 (en) 2020-04-29
KR102539877B1 (ko) 2023-06-05
US20210347768A1 (en) 2021-11-11
WO2018049328A1 (en) 2018-03-15
US10865201B2 (en) 2020-12-15
CN110121343A (zh) 2019-08-13
KR20190068535A (ko) 2019-06-18
US20190218208A1 (en) 2019-07-18
US11919891B2 (en) 2024-03-05
CA3041038A1 (en) 2018-03-15
EP3509588B1 (en) 2023-06-07
EP3509588C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
CN110121343B (zh) 用作gpr120调节剂的双环化合物
US12116362B2 (en) Monocyclic compounds useful as GPR120 modulators
CN104470898B (zh) 环烷基甲酸类衍生物、其制备方法及其在医药上的应用
JP6552061B2 (ja) 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用
JP2010500372A (ja) オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
JP2019077713A (ja) ＮＲ２ＢのＮ−アルキルアリール−５−オキシアリール−オクタヒドロ−シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
TW201625533A (zh) Ｋｃｎｑ ２至５通道活化劑
JP6293266B2 (ja) 高血圧及び／又は線維症の処置用組成物
CN116438174A (zh) 化合物及其作为mif抑制剂的用途
KR20090074179A (ko) Ｐｐａｒ 조절제로서 유용한 １ｈ­인돌­２­카르복실산 유도체
JP2009506127A (ja) 糖尿病の処置に有用なアニリノピラゾール誘導体
JP2006516628A (ja) 飽和キノキサリン誘導体および代謝型グルタミン酸受容体リガンドとしてのそれらの使用
TW201708226A (zh) 吲哚衍生物
JP5893155B2 (ja) Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物
CA3041038C (en) Bicyclic compounds useful as gpr120 modulators
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators
JP2024546944A (ja) Ｒｘｆｐ１アゴニストとしてのナフタレンおよびキノリン類似体
HK40005332B (en) Monocyclic compounds useful as gpr120 modulators
HK40005332A (en) Monocyclic compounds useful as gpr120 modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200909

Address after: Massachusetts, USA

Applicant after: Overall health

Address before: California, USA

Applicant before: NUMERATE, Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Massachusetts, USA

Patentee after: Valo health Co.,Ltd.

Address before: Massachusetts, USA

Patentee before: Overall health

CP01 Change in the name or title of a patent holder